Kymriah deal to stay despite CMS shift on proposed pilot

Novartis AG (NYSE:NVS; SIX:NOVN) said Monday an outcomes-based contract for Kymriah tisagenlecleucel remains in effect with treatment centers. The contract is unaffected by CMS's decision not to pursue the pharma's proposal for a demonstration

Read the full 343 word article

User Sign In